Demographic, Healthcare Access, and Dietary Factors Associated With Thyroid Hormone Treatments for Hypothyroidism.
desiccated thyroid extract
dietary supplements
geographic trends
hypothyroidism
levothyroxine
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
28
03
2023
pmc-release:
16
06
2024
medline:
27
11
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Clinical guidelines have recommended a trial of liothyronine (LT3) with levothyroxine (LT4) in select patients with hypothyroidism. However, little is known about the real-world use of LT3 and desiccated thyroid extract (DTE) and the characteristics of patients treated with LT3 and DTE. (1) Determine national trends of new LT4, LT3, and DTE prescriptions in the United States; (2) determine whether sociodemographic, healthcare access, and dietary factors are associated with different thyroid hormone (TH) therapies. Parallel cross-sectional studies were conducted using 2 datasets: (1) a national patient claims dataset (2010-2020) and (2) the National Health and Nutrition Examination Study (NHANES) dataset (1999-2016). Included participants had a diagnosis of primary or subclinical hypothyroidism. Study outcomes included the impact of demographics and healthcare access on differences in the proportion of TH therapies consisting of LT4, LT3, and DTE (patient claims) and differences in dietary behaviors between DTE-treated participants and LT4-treated matched controls (NHANES). On an average annual basis, 47 711 adults received at least 1 new TH prescription, with 88.3% receiving LT4 monotherapy, 2.0% receiving LT3 therapy, and 9.4% receiving DTE therapy. The proportion receiving DTE therapy increased from 5.4% in 2010 to 10.2% in 2020. In the analysis between states, high primary care and endocrinology physician densities were associated with increased use of LT4 monotherapy (odds ratio 2.51, P < .001 and odds ratio 2.71, P < .001). DTE-treated NHANES participants (n = 73) consumed more dietary supplements compared to LT4-treated participants (n = 146) (4.7 vs 2.1, P < .001). The proportion of new TH therapies containing DTE for hypothyroidism doubled since 2010 while LT3 therapies remained stable. DTE treatment was associated with decreased physician density and increased dietary supplement use.
Identifiants
pubmed: 37327351
pii: 7192108
doi: 10.1210/clinem/dgad331
pmc: PMC10655529
doi:
Substances chimiques
Thyroxine
Q51BO43MG4
Triiodothyronine
06LU7C9H1V
Thyroid Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1614-e1623Subventions
Organisme : NIH HHS
ID : 5T32DK007011-46
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
BMC Endocr Disord. 2022 May 3;22(1):117
pubmed: 35501788
Clin Endocrinol (Oxf). 2016 Jun;84(6):799-808
pubmed: 26010808
Arch Intern Med. 2000 Feb 28;160(4):526-34
pubmed: 10695693
Thyroid Res. 2018 Jan 17;11:1
pubmed: 29375671
JAMA Intern Med. 2021 Oct 1;181(10):1402-1405
pubmed: 34152370
Thyroid. 2007 Dec;17(12):1211-23
pubmed: 18177256
J Clin Endocrinol Metab. 2018 Aug 15;:
pubmed: 30124904
Thyroid Res. 2022 Mar 5;15(1):3
pubmed: 35248144
Hormones (Athens). 2004 Apr-Jun;3(2):120-6
pubmed: 16982586
Thyroid. 2021 Feb;31(2):156-182
pubmed: 33276704
J Am Board Fam Med. 2020 Mar-Apr;33(2):284-288
pubmed: 32179612
JAMA Intern Med. 2013 Mar 11;173(5):355-61
pubmed: 23381623
JAMA Netw Open. 2021 Jan 4;4(1):e2033994
pubmed: 33481030
Drugs R D. 2016 Mar;16(1):53-68
pubmed: 26689565
Thyroid. 2018 Nov;28(11):1416-1424
pubmed: 30289349
Endocr Pract. 2022 Mar;28(3):257-264
pubmed: 34890786
Thyroid. 2019 Nov;29(11):1536-1544
pubmed: 31436135
Thyroid. 2019 Jan;29(1):44-52
pubmed: 30375273
Clin Endocrinol (Oxf). 2021 Mar;94(3):513-520
pubmed: 32978985
Thyroid. 2016 Mar;26(3):347-55
pubmed: 26700485
Acta Sci Pol Technol Aliment. 2021 Oct-Dec;20(4):375-381
pubmed: 34724363
BMC Geriatr. 2022 Jun 25;22(1):522
pubmed: 35752783
J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4400-e4413
pubmed: 34185829
Clin Endocrinol (Oxf). 2023 Feb;98(2):238-248
pubmed: 35975405
Thyroid. 2014 Dec;24(12):1670-751
pubmed: 25266247
Thyroid. 2013 Oct;23(10):1233-7
pubmed: 23758055
Thyroid. 2012 Dec;22(12):1200-35
pubmed: 22954017
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):377-83
pubmed: 25122491
JAMA Intern Med. 2019 Apr 1;179(4):506-514
pubmed: 30776056
J Clin Endocrinol Metab. 2023 Nov 17;108(12):e1614-e1623
pubmed: 37327351
Endocrinol Diabetes Nutr (Engl Ed). 2022 Aug-Sep;69(7):520-529
pubmed: 36084989
Thyroid. 2018 Jun;28(6):707-721
pubmed: 29620972
Lancet Diabetes Endocrinol. 2017 Apr;5(4):246-248
pubmed: 28029536
Front Endocrinol (Lausanne). 2019 Jan 30;10:31
pubmed: 30761091
Eur Thyroid J. 2012 Jul;1(2):55-71
pubmed: 24782999
Eur J Endocrinol. 2012 Sep;167(3):373-8
pubmed: 22711760
Thyroid. 2020 Oct;30(10):1399-1413
pubmed: 32279609
J Clin Endocrinol Metab. 2002 Feb;87(2):489-99
pubmed: 11836274
Ir J Med Sci. 2023 Oct;192(5):2179-2187
pubmed: 36482281